Zenomics. Inc. Magnify at California NanoSystems Institute, Los Angeles, CA, United States.
School of Dentistry, The University of Queensland, Brisbane, QLD, Australia.
Front Immunol. 2021 Nov 25;12:771201. doi: 10.3389/fimmu.2021.771201. eCollection 2021.
Although breast cancer has been previously considered "cold" tumors, numerous studies are currently conducted to explore the great potentials of immunotherapies in improving breast cancer patient outcomes. In addition to the focus on stimulating adaptive immunity for antitumor responses, growing evidence showed the importance of triggering host innate immunity to eradicate established tumors and/or control tumor metastasis of breast cancer. In this review, we first briefly introduce the breast tumor immune microenvironment. We also discuss innate immune targets and pathways and mechanisms of their synergy with the adaptive antitumor response and other treatment strategies. Lastly, we review clinical trials targeting innate immune pathways for breast cancer therapies.
尽管乳腺癌以前被认为是“冷”肿瘤,但目前正在进行许多研究,以探索免疫疗法在改善乳腺癌患者预后方面的巨大潜力。除了关注刺激适应性免疫以产生抗肿瘤反应外,越来越多的证据表明触发宿主固有免疫以根除已建立的肿瘤和/或控制乳腺癌的肿瘤转移的重要性。在这篇综述中,我们首先简要介绍了乳腺肿瘤免疫微环境。我们还讨论了固有免疫靶点及其与适应性抗肿瘤反应和其他治疗策略协同作用的途径和机制。最后,我们回顾了针对乳腺癌治疗的固有免疫途径的临床试验。